Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.63 |
| ▸ | CTSS | P25774 | 1/20 | 0.63 |
| ▸ | CTSK | P43235 | 1/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.62 |
| ▸ | TACR1 | P25103 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401065 | 1.00 | CTSL (0.63) | CTSLCTSSCTSKHDAC3HDAC4 | |
| SCHEMBL6833548 | 1.00 | CTSL (0.63) | CTSLCTSSCTSKHDAC3HDAC4 | |
| SCHEMBL3560147 | 1.00 | CTSL (0.63) | CTSLCTSSCTSKHDAC3HDAC4 | |
| SCHEMBL29398124 | 1.00 | CTSL (0.63) | CTSLCTSSCTSKHDAC3HDAC4 | |
| SCHEMBL4667151 | 0.91 | CTSL (0.61) | CTSLCTSSCTSKHDAC3HDAC4 | |
| SCHEMBL6409098 | 0.90 | CTSL (0.62) | CTSLCTSSCTSKHDAC3HDAC4 | |
| SCHEMBL21466531 | 0.90 | CTSL (0.62) | CTSLCTSSCTSKHDAC3HDAC4 | |
| SCHEMBL8592427 | 0.90 | CTSL (0.62) | CTSLCTSSCTSKHDAC3HDAC4 | |
| SCHEMBL23127370 | 0.89 | ACE (0.66) | CTSLCTSSCTSKHDAC3HDAC4 | |
| SCHEMBL21309842 | 0.89 | CTSL (0.61) | CTSLCTSSCTSKHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-4101855-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-02 | — | — | EP | disclosed |
| EP-3870234-B1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR SA (ES) | 2022-12-21 | — | — | EP | disclosed |
| EP-4101855-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2022-12-14 | — | — | EP | disclosed |
| US-20220193035-A1 | INDOLE COMPOUNDS FOR USE IN NEURORESTORATION | GALIMEDIX THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-9878992-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878992-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-6235717-B1 | Pharmaceutical compounds | GLAXO WELLCOME INC. | 2001-05-22 | — | — | US | disclosed |
| EP-1029869-A1 | Endothelin converting enzyme inhibitors | THE WELLCOME FOUNDATION LIMITED (GB) | 2000-08-23 | — | — | EP | disclosed |
| EP-0677059-A1 | ENDOTHELIN CONVERTING ENZYME INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-10-18 | — | — | EP | disclosed |
| US-5382670-A | Platelet activating factor antagonists | ABBOTT LABORATORIES (US) | 1995-01-17 | — | — | US | disclosed |
| WO-1994015956-A1 | ENDOTHELIN CONVERTING ENZYME INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-07-21 | — | — | WO | disclosed |
| EP-0574494-A4 | INDOLES USEFUL AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LAB (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0574494-A1 | INDOLES USEFUL AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1993-12-22 | — | — | EP | disclosed |
| WO-1992014732-A1 | INDOLES USEFUL AS PLATELET ACTIVATING FACTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1992-09-03 | — | — | WO | disclosed |
| EP-0499987-A1 | Platelet activating factor antagonists | ABBOTT LABORATORIES (US) | 1992-08-26 | — | — | EP | disclosed |
| US-5120749-A | Treatment of anaphylactic shock, respiratory distress syndrome, acute inflammation, delayed cellulosr immunity, parturtition, fetal lung maturation, and cellular differentiation | ABBOTT LABORATORIES (US) | 1992-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193035-A1 | INDOLE COMPOUNDS FOR USE IN NEURORESTORATION | AANAT, INMT, TPH2 | CTSL 2044/4885CTSS 1083/4885CTSK 896/4885 |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | TGFBR1, TGFBR2, ACVR1 | CTSL 2340/4885CTSS 2878/4885CTSK 2660/4885 |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | SMAD3, TGFBR1, TGFBR2 | CTSL 2097/4885CTSS 2291/4885CTSK 2029/4885 |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | CTSL 1780/4885CTSS 2067/4885CTSK 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.